Ipamorelin

Ipamorelin

$180.00

Ipamorelin is a synthetic peptide that acts as a selective growth hormone secretagogue, stimulating the release of growth hormone (GH) from the pituitary gland. It is a potent and specific compound, distinguishing itself from other peptides by having minimal effects on cortisol and prolactin levels. As a result, it is often used in research studies focused on growth hormone regulation, fat loss, and muscle growth, among other areas.

Ipamorelin has gained significant attention for its ability to promote an increase in endogenous GH levels, leading to enhanced protein synthesis, fat metabolism, and muscle regeneration. It is frequently explored for its potential therapeutic benefits in conditions like growth hormone deficiency, age-related muscle loss (sarcopenia), and obesity-related disorders. Researchers are also investigating Ipamorelin’s potential to improve bone density and enhance tissue repair processes.

This 10mg formulation of Ipamorelin is designed for research purposes only and is produced with the highest quality standards to ensure purity and efficacy in scientific investigations. It should be used exclusively in controlled laboratory environments for in vitro and in vivo research.

0% 1 - 4 $180.00
10% 5 - 9 $162.00
20% 10 + $144.00
  • Free shipping on orders over $200
  • Discounts: Calculated in cart.

Description

Ipamorelin is a synthetic peptide that mimics the action of growth hormone-releasing hormone (GHRH). It is known as a growth hormone secretagogue due to its ability to stimulate the pituitary gland to secrete endogenous growth hormone (GH). Unlike other peptides that release GH, Ipamorelin does so selectively, without significantly affecting the secretion of other hormones like cortisol or prolactin. This makes it an attractive peptide for research into growth hormone regulation and its various physiological effects.

The primary mechanism of action of Ipamorelin is its binding to the GHS-R1a receptor, which then triggers the release of GH. GH has a wide range of biological effects on the body, including promoting the growth of tissues and muscles, enhancing fat metabolism, and stimulating the production of insulin-like growth factor 1 (IGF-1). IGF-1, in turn, plays a vital role in cell growth, tissue repair, and muscle regeneration.

Research on Ipamorelin has primarily focused on its potential to support muscle regeneration and fat metabolism. In studies involving growth hormone deficiency or age-related muscle loss (sarcopenia), Ipamorelin has been shown to enhance muscle mass and strength. This peptide is of particular interest in the field of regenerative medicine, where it could be used to support the healing of tissues, especially in cases of muscle injuries or degenerative diseases.

One of the key advantages of Ipamorelin over other GH secretagogues is its selective action. While other peptides may lead to increased levels of cortisol (a stress hormone) and prolactin, Ipamorelin specifically targets growth hormone release with minimal side effects. This characteristic makes it a preferred option for research into the long-term effects of increased GH levels, as it reduces the risk of unwanted hormonal imbalances.

Ipamorelin is also being researched for its potential applications in obesity treatment. By stimulating the release of GH, it may promote fat metabolism and support fat loss. This makes it a valuable tool in studies aimed at understanding and addressing obesity-related conditions, such as metabolic syndrome and type 2 diabetes.

Additionally, Ipamorelin has been explored for its potential role in improving bone density and supporting overall bone health. GH and IGF-1 are essential for bone growth and remodeling, and Ipamorelin’s ability to stimulate GH release may help improve bone mineral density in individuals with age-related bone loss or conditions like osteoporosis.

In summary, Ipamorelin is a promising peptide for a variety of research applications, particularly those involving growth hormone regulation, muscle regeneration, fat metabolism, and bone health. This 10mg formulation is intended for research purposes only and must be handled according to safety guidelines in controlled laboratory environments.

For research use only. Not intended for human or animal use.

Product Data:

  • Chemical Name: Ipamorelin
  • CAS Number: 170851-70-4
  • Molecular Formula: C38H49N7O5
  • Molecular Weight: 711.9 g/mol
  • Sequence: Aib-His-D-2-Nal-D-Phg-(2S)-Pro-Ala-Ser
  • PubChem CID: 57322969

Research

Ipamorelin has become a valuable research tool in the study of growth hormone regulation due to its high receptor specificity and favorable pharmacological profile. Researchers use this compound to investigate GH-dependent physiological processes in a variety of models, ranging from muscle growth and repair to metabolic function and aging.

One of the distinguishing features of Ipamorelin is its minimal interaction with the hypothalamic-pituitary-adrenal (HPA) axis. Unlike other secretagogues such as GHRP-6, Ipamorelin does not significantly elevate cortisol or prolactin levels, making it an ideal candidate for isolated GH studies. This selectivity allows researchers to study the effects of GH and IGF-1 without the confounding influence of stress-related hormones.

In rodent models, Ipamorelin has demonstrated the ability to enhance lean body mass and reduce adiposity when administered over extended periods. These studies often show increases in circulating IGF-1, improved nitrogen retention, and enhanced cellular regeneration, all of which contribute to anabolic processes. The peptide has also been examined in models simulating catabolic states, such as post-surgical recovery or chronic illness, where it supports muscle protein synthesis and recovery.

Ipamorelin's potential role in aging research is also noteworthy. With advancing age, natural GH production declines, leading to reduced bone density, muscle mass, and metabolic rate. Ipamorelin provides a controlled model for mimicking GH restoration and studying its downstream effects on these age-associated markers. In particular, its pulsatile nature helps simulate physiological GH secretion patterns, which are crucial for minimizing negative feedback mechanisms and maintaining receptor sensitivity.

Additionally, the peptide’s impact on bone remodeling has garnered interest. Preliminary data suggest that Ipamorelin may support osteoblast activity and mineral deposition, making it a candidate for further study in conditions such as osteoporosis or bone injuries.

Research also explores the neuroprotective effects of GH and IGF-1, which are indirectly stimulated by Ipamorelin. These studies have examined the compound’s role in neuronal plasticity, neurogenesis, and even cognitive function under stress or injury conditions.

In summary, Ipamorelin is a potent, selective, and well-tolerated peptide for growth hormone research. Its advantages include strong receptor affinity, low side effect profile, and compatibility with other secretagogues. These features make it a cornerstone in experimental setups aimed at understanding the GH/IGF-1 axis, anabolic regulation, tissue regeneration, and endocrine function.

For research use only. Not for human or veterinary applications.

References:

  1. K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]
  2. N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]
  3. J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]
  4. N. K. Aagaard et al., “Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 19, no. 5, pp. 426–431, Oct. 2009. [PubMed]
  5. E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]
  6. D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]
  7. B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus,” J. Exp. Pharmacol., vol. 4, pp. 149–155, Oct. 2012. [PubMed]
  8. M. M. Fowkes, T. Lalonde, L. Yu, S. Dhanvantari, M. S. Kovacs, and L. G. Luyt, “Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor,” Eur. J. Med. Chem., vol. 157, pp. 1500–1511, Sep. 2018. [Science Direct]

 

Related products

Scroll to Top
0